Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction

Wenyu Fu; Yujianan Chen; Kaidi Wang; Aubryanna Hettinghouse; Wenhuo Hu; Jing-Quan Wang; Zi-Ning Lei; Zhe-Sheng Chen; Kenneth A. Stapleford; Chuan-ju Liu

doi:10.1007/s13238-020-00803-w

Volume 12 Issue 7

Jul. 2021

Turn off MathJax

Article Contents

Article Navigation > Protein&Cell > 2021 > 12(7): 586-591

Wenyu Fu, Yujianan Chen, Kaidi Wang, Aubryanna Hettinghouse, Wenhuo Hu, Jing-Quan Wang, Zi-Ning Lei, Zhe-Sheng Chen, Kenneth A. Stapleford, Chuan-ju Liu. Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction[J]. Protein&Cell, 2021, 12(7): 586-591. doi: 10.1007/s13238-020-00803-w

Citation:

Wenyu Fu, Yujianan Chen, Kaidi Wang, Aubryanna Hettinghouse, Wenhuo Hu, Jing-Quan Wang, Zi-Ning Lei, Zhe-Sheng Chen, Kenneth A. Stapleford, Chuan-ju Liu. Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction[J]. Protein&Cell, 2021, 12(7): 586-591. doi: 10.1007/s13238-020-00803-w

Citation:

Wenyu Fu, Yujianan Chen, Kaidi Wang, Aubryanna Hettinghouse, Wenhuo Hu, Jing-Quan Wang, Zi-Ning Lei, Zhe-Sheng Chen, Kenneth A. Stapleford, Chuan-ju Liu. Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction[J]. Protein&Cell, 2021, 12(7): 586-591. doi: 10.1007/s13238-020-00803-w

PDF( 811 KB)

Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction

doi: 10.1007/s13238-020-00803-w

1 Department of Orthopaedic Surgery, New York University Medical Center, 301 East 17 th Street, New York, NY 10003, USA;
2 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;
3 Department of Pharmaceutical Science, College of Pharmacy and Health Sciences, St. John's University, New York, NY 11439, USA;
4 Department of Microbiology, New York University School of Medicine, New York, NY 10016, USA;
5 Department of Cell Biology, New York University School of Medicine, New York, NY 10016, USA

Funds:

This work was supported partly by NIH research grants R01AR062207, R01AR061484, R01NS103931, and R01AR076900 (CJ Liu).

Publish Date: 2021-07-08

Abstract

FullText(HTML)

References(15)

References

[1]	Castañeda-Arriaga R, Pérez-González A, Galano A (2018) Chemical Protectors against the Toxic Effects of Paracetamol (Acetaminophen) and Its Meta Analogue:Preventing Protein Arylation. ACS Omega 3:18582-18591
[2]	De Flora S, Grassi C, Carati L (1997) Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 10:1535-1541
[3]	Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, Cinatl J Jr (2010) N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol 79:413-420
[4]	Ghezzi P, Ungheri D (2004) Synergistic combination of N-acetylcysteine and ribavirin to protect from lethal influenza viral infection in a mouse model. Int J Immunopathol Pharmacol 17:99-102
[5]	Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL et al (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583:459-468
[6]	Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP (2020) Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients 12:988
[7]	Gu C, Wu Y, Guo H, Zhu Y, Xu W, Wang Y, Sun Z, Cai X, Li Y, Liu J et al (2020) Potent antiviral effect of protoporphyrin IX and verteporfin on SARS-CoV-2 infection. bioRxiv, 2020.2004.2030.071290
[8]	Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C et al (2020) Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582:289-293
[9]	Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M (2020) Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 368:860-868
[10]	Mitchell F (2020) Vitamin-D and COVID-19:do deficient risk a poorer outcome? Lancet Diabetes Endocrinol. 8:570
[11]	Nolin TD, Ouseph R, Himmelfarb J, McMenamin ME, Ward RA (2010) Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease. Clin J Am Soc Nephrol 5:1588-1594
[12]	Poe FL, Corn J (2020) N-Acetylcysteine:A potential therapeutic agent for SARS-CoV-2. Med Hypotheses 143:109862
[13]	Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L et al (2020) A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature 584:120-124
[14]	Zemb P, Bergman P, Camargo CA Jr, Cavalier E, Cormier C, Courbebaisse M, Hollis B, Minisola S, Pilz S, Pludowski P et al (2020) Vitamin D deficiency and COVID-19 pandemic. J Glob Antimicrob Resist 29:133-134
[15]	Zhang C, Cui M, Cui Y, Hettinghouse A, Liu CJ (2019) A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction. J Vis Exp 27, doi: 10.3791/59656

Relative Articles(20)

Relative Articles

[1]	Le Chang, Lei Zhao, Yan Xiao, Tingting Xu, Lan Chen, Yan Cai, Xiaojing Dong, Conghui Wang, Xia Xiao, Lili Ren, Lunan Wang. Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019. Protein&Cell, 2023, 14(1): 28-36. doi: 10.1093/procel/pwac013
[2]	Fei Feng, Yunkai Zhu, Yanlong Ma, Yuyan Wang, Yin Yu, Xinran Sun, Yuanlin Song, Zhugui Shao, Xinxin Huang, Ying Liao, Jingyun Ma, Yuping He, Mingyuan Wang, Longhai Tang, Yaowei Huang, Jincun Zhao, Qiang Ding, Youhua Xie, Qiliang Cai, Hui Xiao, Chun Li, Zhenghong Yuan, Rong Zhang. A CRISPR activation screen identifies genes that enhance SARS-CoV-2 infection. Protein&Cell, 2023, 14(1): 64-68. doi: 10.1093/procel/pwac036
[3]	Daming Zuo, Yu Chen, Jian-piaoCai, Hao-Yang Yuan, Jun-Qi Wu, Yue Yin, Jing-Wen Xie, Jing-Min Lin, Jia Luo, Yang Feng, Long-Jiao Ge, Jia Zhou, Ronald J. Quinn, San-Jun Zhao, Xing Tong, Dong-Yan Jin, Shuofeng Yuan, Shao-Xing Dai, Min Xu. A hnRNPA2B1 agonist effectively inhibits HBV and SARS-CoV-2 omicron in vivo. Protein&Cell, 2023, 14(1): 37-50. doi: 10.1093/procel/pwac027
[4]	Simeng Zhao, Fengjiang Liu, Shizhen Qiu, Qiaoshuai Lan, Yiran Wu, Wei Xu, Junzi Ke, Jie Yang, Xiaoyan Liu, Kun Wang, Hangtian Guo, Shuai Xia, Fangfang Zhang, Jiabei Wang, Xiaowen Hu, Lu Lu, Shibo Jiang, Suwen Zhao, Lianxin Liu, Youhua Xie, Xiuna Yang, Haopeng Wang, Guisheng Zhong. A core epitope targeting antibody of SARS-CoV-2. Protein&Cell, 2023, 14(1): 74-78. doi: 10.1093/procel/pwac042
[5]	Dali Tong, Mei Zhang, Yunru Yang, Han Xia, Haiyang Tong, Huajun Zhang, Weihong Zeng, Muziying Liu, Yan Wu, Huan Ma, Xue Hu, Weiyong Liu, Yuan Cai, Yanfeng Yao, Yichuan Yao, Kunpeng Liu, Shifang Shan, Yajuan Li, Ge Gao, Weiwei Guo, Yun Peng, Shaohong Chen, Juhong Rao, Jiaxuan Zhao, Juan Min, Qingjun Zhu, Yanmin Zheng, Lianxin Liu, Chao Shan, Kai Zhong, Zilong Qiu, Tengchuan Jin, Sandra Chiu, Zhiming Yuan, Tian Xue. Single-dose AAV-based vaccine induces a high level of neutralizing antibodies against SARS-CoV-2 in rhesus macaques. Protein&Cell, 2023, 14(1): 69-73. doi: 10.1093/procel/pwac020
[6]	Yi Zang, Mingbo Su, Qingxing Wang, Xi Cheng, Wenru Zhang, Yao Zhao, Tong Chen, Yingyan Jiang, Qiang Shen, Juan Du, Qiuxiang Tan, Peipei Wang, Lixin Gao, Zhenming Jin, Mengmeng Zhang, Cong Li, Ya Zhu, Bo Feng, Bixi Tang, Han Xie, Ming-Wei Wang, Mingyue Zheng, Xiaoyan Pan, Haitao Yang, Yechun Xu, Beili Wu, Leike Zhang, Zihe Rao, Xiuna Yang, Hualiang Jiang, Gengfu Xiao, Qiang Zhao, Jia Li. High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors. Protein&Cell, 2023, 14(1): 17-27. doi: 10.1093/procel/pwac016
[7]	Yu-Sheng Chen, Shuaiyao Lu, Bing Zhang, Tingfu Du, Wen-Jie Li, Meng Lei, Yanan Zhou, Yong Zhang, Penghui Liu, Yong-Qiao Sun, Yong-Liang Zhao, Ying Yang, Xiaozhong Peng, Yun-Gui Yang. Comprehensive analysis of RNA-seq and whole genome sequencing data reveals no evidence for SARS-CoV-2 integrating into host genome. Protein&Cell, 2022, 13(5): 379-385. doi: 10.1007/s13238-021-00861-8
[8]	Yao Zhao, Chao Fang, Qi Zhang, Ruxue Zhang, Xiangbo Zhao, Yinkai Duan, Haofeng Wang, Yan Zhu, Lu Feng, Jinyi Zhao, Maolin Shao, Xiuna Yang, Leike Zhang, Chao Peng, Kailin Yang, Dawei Ma, Zihe Rao, Haitao Yang. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein&Cell, 2022, 13(9): 689-693. doi: 10.1007/s13238-021-00883-2
[9]	Yichen Li, Shuaiyao Lu, Jinge Gu, Wencheng Xia, Shengnan Zhang, Shenqing Zhang, Yan Wang, Chong Zhang, Yunpeng Sun, Jian Lei, Cong Liu, Zhaoming Su, Juntao Yang, Xiaozhong Peng, Dan Li. SARS-CoV-2 impairs the disassembly of stress granules and promotes ALS-associated amyloid aggregation. Protein&Cell, 2022, 13(8): 602-614. doi: 10.1007/s13238-022-00905-7
[10]	Chun-Chun Gao, Man Li, Wei Deng, Chun-Hui Ma, Yu-Sheng Chen, Yong-Qiao Sun, Tingfu Du, Qian-Lan Liu, Wen-Jie Li, Bing Zhang, Lihong Sun, Si-Meng Liu, Fengli Li, Feifei Qi, Yajin Qu, Xinyang Ge, Jiangning Liu, Peng Wang, Yamei Niu, Zhiyong Liang, Yong-Liang Zhao, Bo Huang, Xiao-Zhong Peng, Ying Yang, Chuan Qin, Wei-Min Tong, Yun-Gui Yang. Differential transcriptomic landscapes of multiple organs from SARS-CoV-2 early infected rhesus macaques. Protein&Cell, 2022, 13(12): 920-939. doi: 10.1007/s13238-022-00915-5
[11]	Rui Xiong, Leike Zhang, Shiliang Li, Yuan Sun, Minyi Ding, Yong Wang, Yongliang Zhao, Yan Wu, Weijuan Shang, Xiaming Jiang, Jiwei Shan, Zihao Shen, Yi Tong, Liuxin Xu, Yu Chen, Yingle Liu, Gang Zou, Dimitri Lavillete, Zhenjiang Zhao, Rui Wang, Lili Zhu, Gengfu Xiao, Ke Lan, Honglin Li, Ke Xu. Correction to: Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein&Cell, 2021, 12(1): 76-80. doi: 10.1007/s13238-020-00792-w
[12]	Wanyin Tao, Xiaofang Wang, Guorong Zhang, Meng Guo, Huan Ma, Dan Zhao, Yong Sun, Jun He, Lianxin Liu, Kaiguang Zhang, Yucai Wang, Jianping Weng, Xiaoling Ma, Tengchuan Jin, Shu Zhu. Re-detectable positive SARS-CoV-2 RNA tests in patients who recovered from COVID-19 with intestinal infection. Protein&Cell, 2021, 12(3): 230-235. doi: 10.1007/s13238-020-00778-8
[13]	Dan Zhao, Weifan Xu, Xiaofan Zhang, Xiaoting Wang, Yiyue Ge, Enming Yuan, Yuanpeng Xiong, Shenyang Wu, Shuya Li, Nian Wu, Tingzhong Tian, Xiaolong Feng, Hantao Shu, Peng Lang, Jingxin Li, Fengcai Zhu, Xiaokun Shen, Haitao Li, Pilong Li, Jianyang Zeng. Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2. Protein&Cell, 2021, 12(9): 734-740. doi: 10.1007/s13238-021-00832-z
[14]	Rongjuan Pei, Jianqi Feng, Yecheng Zhang, Hao Sun, Lian Li, Xuejie Yang, Jiangping He, Shuqi Xiao, Jin Xiong, Ying Lin, Kun Wen, Hongwei Zhou, Jiekai Chen, Zhili Rong, Xinwen Chen. Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection. Protein&Cell, 2021, 12(9): 717-733. doi: 10.1007/s13238-020-00811-w
[15]	Xingdong Zhou, Hui Wang, Qun Ji, Mingjuan Du, Yuexia Liang, Huanhuan Li, Fan Li, Hang Shang, Xiujuan Zhu, Wei Wang, Lichun Jiang, Alexey V. Stepanov, Tianyu Ma, Nanxin Gong, Xiaodong Jia, Alexander G. Gabibov, Zhiyong Lou, Yinying Lu, Yu Guo, Hongkai Zhang, Xiaoming Yang. Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine. Protein&Cell, 2021, 12(10): 818-823. doi: 10.1007/s13238-021-00840-z
[16]	Hang-Yu Zhou, Cheng-Yang Ji, Hang Fan, Na Han, Xiao-Feng Li, Aiping Wu, Cheng-Feng Qin. Convergent evolution of SARS-CoV-2 in human and animals. Protein&Cell, 2021, 12(11): 832-835. doi: 10.1007/s13238-021-00847-6
[17]	Yao Zhao, Xiaoyu Du, Yinkai Duan, Xiaoyan Pan, Yifang Sun, Tian You, Lin Han, Zhenming Jin, Weijuan Shang, Jing Yu, Hangtian Guo, Qianying Liu, Yan Wu, Chao Peng, Jun Wang, Chenghao Zhu, Xiuna Yang, Kailin Yang, Ying Lei, Luke W. Guddat, Wenqing Xu, Gengfu Xiao, Lei Sun, Leike Zhang, Zihe Rao, Haitao Yang. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors. Protein&Cell, 2021, 12(11): 876-887. doi: 10.1007/s13238-021-00836-9
[18]	Jinliang Wang, Lei Shuai, Chong Wang, Renqiang Liu, Xijun He, Xianfeng Zhang, Ziruo Sun, Dan Shan, Jinying Ge, Xijun Wang, Ronghong Hua, Gongxun Zhong, Zhiyuan Wen, Zhigao Bu. Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice. Protein&Cell, 2020, 11(10): 776-782. doi: 10.1007/s13238-020-00767-x
[19]	Bing Zhao, Chao Ni, Ran Gao, Yuyan Wang, Li Yang, Jinsong Wei, Ting Lv, Jianqing Liang, Qisheng Zhang, Wei Xu, Youhua Xie, Xiaoyue Wang, Zhenghong Yuan, Junbo Liang, Rong Zhang, Xinhua Lin. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein&Cell, 2020, 11(10): 771-775. doi: 10.1007/s13238-020-00718-6
[20]	Zheng Zhou, Jun-Ming Liao, Peng Zhang, Jun-Bao Fan, Jie Chen, Yi Liang. Parkinson disease drug screening based on the interaction between D₂ dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresis. Protein&Cell, 2011, 2(11): 899-905. doi: 10.1007/s13238-011-1096-0